Among the myriad drugmakers laying out their plans for the future at this year’s J.P. Morgan Healthcare Conference, Takeda ...

Discover outperforming stocks and invest smarter with Top Smart Score StocksFilter, analyze, and streamline your ...

or orexin receptor 2 (OX2R). These receptors regulate sleep and wakefulness, stress responses, and appetite. Drugs like Belsomra block the activity of these neurotransmitters by attaching to the ...

Centessa is rapidly advancing a potential best-in-class and first-in-class portfolio of orexin receptor 2 (OX2R) agonists with a robust series of clinical milestones anticipated this year,” said ...

In the third quarter of 2024, the company made quite some progress with its trials by announcing interim data from a phase 1 trial for its novel orexin receptor 2 (OX2R) and initiated phase 2 ...

Spiromacrocyclic compounds acting as orexin OX2 receptor agonists have been described in an H. Lundbeck A/S patent and reported to be useful for the treatment of type 1 and type 2 narcolepsy.

Announced additional interim data from ongoing Phase 1 clinical study of ORX750, a novel orexin receptor 2 (OX2R) agonist, in acutely sleep-deprived healthy volunteers that further support best-in ...

The company’s primary products include a pipeline of orexin receptor 2 (OX2R) agonists, with a market focus on treating sleep-wake, neurological, neurodegenerative, and psychiatric disorders.